Cancer Biology Platform

Prior to 3DMed, Dr. Gong served as VP of Drug Development and Regulatory Affairs of Beigene, CEO of BL Pharma, and CTO of JOINN Laboratories.

From 1998 to 2008, Dr. Gong worked at US FDA as Reviewer, he conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics.

Dr. Gong is committee member of the Chinese Pharmaceutical Association, Council member of AAALAC and Tongxieyi Club, members of editorial board of Chinese Journal of New Drugs, Progress in Pharmaceutical Sciences and DIA advisory committee.

Dr. Gong received his Ph.D. in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.

Program Lead of China “Key Innovative Drug Development Program”

Cancer Biology Platform

David Liu, M.D., Ph.D.

Chief Medical Officer

Dr. David Liu received his Medical Degree from Beijing Medical University in 1993. After a two-year clinical practice in the Department of Orthopedic Oncology at the Beijing Jishuitan Hospital, Dr. Liu received a M.S. degree from the University of Toledo and a Ph.D. degree from MIT. In 2001, Dr. Liu joined AstraZeneca as a scientist with key roles in preclinical oncology programs. In 2005, Dr. Liu joined Bristol-Myers Squibb with leadership roles in the clinical development of ixabepilone, brivanib, dasatinib, nivolumab, and ipilimumab. In 2014, Dr. Liu joined Celgene and successfully led the R2 (revlimid plus rituximab) program in follicular and marginal zone lymphomas which resulted in successful sNDA submissions in the US, Europe, and Japan under his leadership. R2 was subsequently approved by FDA for both indications. Dr. Liu joined 3D Medicines as the Chief Medical Officer in January, 2019.

Dr. Liu is an inventor for over 8 patents; an author of over 25 abstracts and 23 peer reviewed manuscripts in prestigious journals including NEJM, Lancet Oncology, and JCO.


Cancer Biology Platform

Jeffrey Lin Ph.D.

Director, Preclinical Drug R&D

Leads 3DMed bio-marker discovery

Former senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia

Ph.D. in Biochemistry and Molecular Biology from Chinese Academy of Sciences(CAS), Post-Doc from the Chinese Academy of Sciences Institute of Health

Cancer Biology Platform

Richard Xue

Executive Director, Head of Clinical Operation


More than 17 years industry experience in drug development including work with hospitals, clinical research organisations and biopharmaceutical companies.

Previous positions span a range of functions, including clinical monitoring, BD, Change Management, training and project management, most recently as global trial lead at Celgene oversaw a successful pivotal trial resulting in global NDA submissions in FDA, EMA, PMDA and other countries.

Worked in UK, Australia and China, brings extensive knowledge of clinical trial management/planning, research processes, and regulations and guidelines in APAC, EU and North America.

Former member of Royal Pharmaceutical Society of Great Britain and Pharmaceutical Society of Australia. Currently board certified pharmacist in Australia.

Holds a bachelor’s degree in Pharmacy from Monash University in Melbourne, Australia.

Cancer Biology Platform

Haolan Lu, Ph.D., Executive Director

Head of Data Management and Biostatistics

Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology drugs global registration and approvals including two immuno-oncology pioneering drugs: Opdivo (nivolumab) and Yervoy (ipilimumab).

Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC;

Ph.D. in Biostatistics from University of Minnesota